SUMMARY INTRODUCTION. Accepted for publication 11 May 2005
|
|
- Gabriella Hunter
- 5 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 2005; 22: doi: /j x Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay results from the Cochrane Collaboration G. I. LEONTIADIS*, V. K. SHARMA &C.W.HOWDENà *Division of Gastroenterology, First Department of Medicine, University of Thessaloniki School of Medicine, AHEPA Hospital, Thessaloniki, Greece; Division of Gastroenterology, Mayo Clinic, Scottsdale, AZ, USA; àdivision of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Accepted for publication 11 May 2005 SUMMARY Background: Proton-pump inhibitors reduce re-bleeding and surgical intervention, but not mortality, after ulcer bleeding. Aim: To examine the effects of proton-pump inhibitor treatment on transfusion requirements and length of hospital stay in patients with ulcer bleeding. Methods: For the Cochrane Collaboration meta-analysis of randomized-controlled trials of proton-pump inhibitor therapy for ulcer bleeding, outcomes of transfusion requirements and hospital stay were summarized, respectively, as mean (±s.d.) units transfused and hospital days. We calculated weighted mean difference with 95% confidence interval. We also performed subgroup analyses according to geographical origin of the randomized-controlled trials. Results: There was significant heterogeneity among randomized-controlled trials for either outcome. Overall, proton-pump inhibitor treatment marginally reduced transfusion requirements (WMD ¼ )0.6 units; 95% CI: )1.1 to 0; P ¼ 0.05) and length of hospitalization (WMD ¼ )1.1 days; 95% CI: )1.5 to )0.7; P < ). Most of the randomized-controlled trials did not state precise criteria for administering blood transfusion and discharging patients, thereby limiting the strength of conclusions on the pooled effects. Conclusions: Proton-pump inhibitor treatment for ulcer bleeding produces small, but potentially important, reductions in transfusion requirements and length of hospitalization. INTRODUCTION Peptic ulcer is the most frequent cause of acute upper gastrointestinal tract bleeding resulting in hospitalization. 1 There is a substantive clinical and economic burden associated with the management of patients with ulcer bleeding. Proton-pump inhibitors (PPIs) are frequently used as part of initial management. The Correspondence to: Dr C. W. Howden, Division of Gastroenterology, Northwestern University, Feinberg School of Medicine, 676 N. St Clair Street, Suite 1400, Chicago, IL 60611, USA. c-howden@northwestern.edu Cochrane Collaboration systematic review and metaanalysis of randomized-controlled trials (RCTs) of PPI treatment for ulcer bleeding found no significant effect on 30-day all-cause mortality, which was the predetermined primary end-point. 2, 3 PPI treatment did significantly reduce rates of ulcer re-bleeding and surgical intervention, which were predefined secondary endpoints. Some RCTs also provided information on other clinically relevant end-points including blood transfusion requirements and length of hospital stay. Analyses of those end-points were not included in our original publication, 3 and are now reported here. Ó 2005 Blackwell Publishing Ltd 169
2 170 G. I. LEONTIADIS et al. MATERIALS AND METHODS The search strategy and methods used for the Cochrane Collaboration systematic review and meta-analysis of RCTs comparing PPI treatment with placebo or an histamine-2 receptor antagonist (H 2 RA) for bleeding ulcer are available on-line from the Cochrane library ( 2 Details about the design of individual RCTs are available on-line 2 and in our initial publication. 3 Briefly, we performed computerized searches of MEDLINE, EMBASE and the Cochrane Collaboration s trials register for RCTs that compared a PPI (either orally or i.v.) with placebo or an H 2 RA for endoscopically confirmed bleeding peptic ulcer. We supplemented that with a hand search of conference proceedings and by requesting any unpublished information from relevant pharmaceutical companies. Two assessors independently reviewed each identified RCT and extracted relevant data onto a purpose-designed form. Any disagreements were resolved by consensus. For inclusion, an RCT had to have confirmed the diagnosis of ulcer bleeding by endoscopy and randomized patients to either the PPI or control treatment. Any other treatment intervention, including endoscopic haemostatic treatment had to have been applied to patients in each arm. RCTs had to have reported at least one of the outcomes of all-cause mortality, re-bleeding and surgical intervention. We also extracted all available information on blood transfusion requirements and length of hospital stay. Where available, the specific criteria used to determine indications for transfusion and discharge from hospital were recorded. Transfusion requirements were reported as mean (±s.d.) units of blood transfused. Length of hospital stay was recorded as mean (±s.d.) days in hospital. We performed meta-analysis of outcomes by combining trials by inverse variance methods. The software used was the Cochrane Collaboration s revman (version 4.2.2). Statistical heterogeneity was evaluated; P-values of <0.1 were considered statistically significant. We planned to use a fixed effect model unless we found significant heterogeneity, in which case we planned to use a random effects model. Outcomes were summarized as a weighted mean difference (WMD) with its 95% confidence interval (CI). We explored the robustness of the pooled effect estimates for each outcome by sensitivity analysis. In a post hoc analysis of the Cochrane Collaboration meta-analysis, we reported that RCTs performed in Asia had found quantitatively greater effects of PPI treatment on re-bleeding and surgical intervention than those performed in Europe or elsewhere. 4 Furthermore, the only evidence for a reduction in all-cause mortality with PPI treatment for ulcer bleeding came from a pooled subgroup analysis confined to the Asian RCTs. 4 We therefore also performed subgroup analyses of RCTs for the end-points of transfusion requirements and length of hospital stay according to geographical origin. RESULTS Blood transfusion requirements Eight RCTs provided information on transfusion requirements In four of these, PPI treatment had been compared with placebo; 6 8, 10 the remainder 5, 9, 11, 12 compared PPI treatment with an H 2 RA. Together, these eight RCTs comprised 1197 patients with 595 randomized to PPI treatment and 602 to control. There was statistically significant heterogeneity among these RCTs (P < ). PPI treatment reduced transfusion requirements (WMD ¼ )0.6 units; 95% CI: )1.1 to 0; P ¼ 0.05; Figure 1). This result was not robust to the exclusion of individual trials; by sensitivity analysis, the effect became non-significant when any one of five RCTs 6, 7, 9 11 was excluded. We sought to investigate the causes of the heterogeneity among the eight RCTs reporting transfusion requirements. Observation of the forest plot (Figure 1) suggested that the heterogeneity was due to a possible outlier effect of one trial. 8 By sensitivity analysis, the remaining trials became non-heterogeneous (P ¼ 0.67) when that trial, but not when any of the others, was excluded. Furthermore, the exclusion of that trial increased the statistical significance of the pooled difference in transfusion requirements in favour of PPI treatment (WMD ¼)0.3; 95% CI: )0.6 to )0.1; P ¼ 0.01). A funnel plot (Figure 2) was clearly asymmetrical but did not suggest a preponderance of missing small trials with negative results. 7, 8, 10 Three of the trials had been conducted in Asia and five in Europe. 5, 6, 9, 11, 12 The three Asian trials comprised 609 patients and there was significant heterogeneity among them for transfusion requirements (P ¼ ). The pooled WMD was )1.01 units (95% CI: )2.0 to )0.2; P ¼ 0.02). The five European
3 SYSTEMATIC REVIEW: PPIS FOR ULCER BLEEDING 171 Outcome: Transfusion requirements Trial PPI Control WMD (random) WMD (random) N Mean (SD) N Mean (SD) 95% CI 95% CI Perez Flores (1.60) (2.00) [-1.08, 0.48] Lanas (2.60) (2.60) [-2.03, 0.83] Villanueva (2.20) (2.10) 0.20 [-0.71, 1.11] Hasselgren (1.60) (2.30) [-0.63, 0.23] Khuroo (1.00) (2.10) [-2.23, -1.37] Corragio (2.90) (2.90) 0.10 [-1.54, 1.74] Lau (2.50) (3.80) [-1.61, 0.01] Kaviani (1.36) (1.68) [-1.03, -0.05] Total (95% CI) [ 1.12, 0.00] Test for heterogeneity: χ² = 35.86, df = 7 (P < ), I ² = 80.5% Test for overall effect: Z = 1.95 (P = 0.05) Favours PPI Favours control Figure 1. Forest plot of weighted mean differences (WMD) and 95% confidence intervals (CI) concerning transfusion requirements (in units of blood transfused) for individual randomized-controlled trials (RCTs) and pooled data. SE of weighted mean difference Outcome: Transfusion requirements Weighted mean difference Figure 2. Funnel plot of included trials for transfusion requirements. trials comprised 588 patients and there was no significant heterogeneity among them (P ¼ 0.88). The pooled WMD was )0.2 units (95% CI: )0.5 to 0.2; P ¼ 0.31). In the above analysis all three trials that had been conducted in Asia had used placebo as a comparator while only one 6 of the five European trials had done so. Prompted by this observation, we performed a post hoc subgroup analysis of the above trials according to the comparator treatment. For the four European trials that compared PPI with H 2 RA, 5, 9, 11, 12 WMD was )0.1 (95% CI: )0.7 to 0.4). For the one European 6 and three Asian 7, 8, 10 trials that compared PPI with placebo, WMD was )0.8 (95% CI: )1.6 to 0.05). Length of hospital stay Seven trials reported length of hospital stay as mean (±s.d.) days in hospital. 5, 7 9, Three compared PPI treatment with placebo; 7, 8, 13 the remaining four compared it with an H 2 RA. 5, 9, 11, 12 These seven trials included a total of 801 patients with 398 randomized to PPI treatment and 403 to control. There was statistically significant heterogeneity among them (P ¼ 0.07). Figure 3 shows that WMD for each RCT was in favour of PPI treatment, although statistical significance was only reached in three trials; 7, 8, 13 the pooled WMD for length of hospital stay was )1.1 days (95% CI: )1.5 to )0.7; P < ). By sensitivity analysis, this result remained statistically significant when any single trial was excluded. A funnel plot showed no asymmetry, suggesting no publication bias (Figure 4). In investigating possible sources of heterogeneity among these trials, inspection of the forest plot (Figure 3) suggested 7, 13 that this was due to results of two of the trials. Although both of these trials demonstrated a statistically significant reduction in length of hospital stay with PPI treatment, the effect was more pronounced in the trial by Javid et al. 13 than in that by Kavianni et al. 7 with no overlapping of their respective 95% CI for WMD (Figure 3). These trials had similar design characteristics including discharge criteria. Kavianni et al. 7 included only patients with active bleeding or non-bleeding visible vessel, while Javid et al. 13 also included patients with adherent clot. Javid et al. 13 also included relatively fewer patients with gastric ulcer (15 of 166 vs. 37 of 112; P ¼ ). The different outcomes on hospital stay are not adequately explained by these differences. If either trial was excluded, the remaining trials became non-heterogeneous, while the pooled effect of the
4 172 G. I. LEONTIADIS et al. Outcome: Length of hospital stay Trial PPI Control WMD (random) WMD (random) N Mean (SD) N Mean (SD) 95% CI 95% CI Perez Flores (3.10) (3.80) [-2.60, 0.40] Lanas (8.80) (5.40) [-5.14, 2.74] Villanueva (13.00) (14.00) [-6.73, 4.73] Khuroo (2.10) (2.10) [-1.95, -0.85] Corragio (4.00) (3.00) [-3.00, 1.00] Javid (1.10) (0.70) [-1.68, -1.12] Kaviani (1.20) (1.60) [-0.95, -0.05] Total (95% CI) [ 1.54, -0.67] Test for heterogeneity: χ² = 11.71, df = 6 (P = 0.07), I ² = 48.7% Test for overall effect: Z = 5.03 (P < ) Favours PPI Favours control Figure 3. Forest plot of weighted mean differences (WMD) and 95% confidence intervals (CI) concerning length of hospital stay (in days) for individual randomized-controlled trials (RCTs) and pooled data. SE of weighted mean difference Outcome: Length of hospital stay Weighted mean difference Figure 4. Funnel plot of included trials for length of hospital stay. Europe. 5, 9, 11, 12 The three Asian trials comprised 535 patients, and there was significant heterogeneity among them for length of hospital stay (P ¼ 0.003). The pooled WMD was )1.1 days (95% CI: )1.7 to )0.5; P ¼ ). The four European trials comprised a total of 166 patients with no significant heterogeneity among them (P ¼ 1.00). The pooled WMD was )1.1 days (95% CI: )2.2 to 0.1; P ¼ 0.06). In the above analysis all three Asian trials had compared PPI against placebo, while all four European trials had compared PPI against H 2 RA. Thus, the post hoc analysis of the above trials according to comparator treatment produced numerically identical results: the reduction in hospital stay was statistically significant only in the trials that used placebo as comparator treatment. DISCUSSION analysis remained statistically significant in favour of PPI treatment. With the exclusion of the trial by Javid et al., 13 there was no significant heterogeneity (P ¼ 0.29), and the pooled WMD was )0.9 days (95% CI: )1.4 to )0.5). With the exclusion of the trial by Kaviani et al., 7 there was no significant heterogeneity (P ¼ 1.00), and the pooled WMD was )1.4 days (95% CI: )1.6 to )1.1). As the effect of treatment would be expected to be attenuated in patients with in-hospital onset of bleeding, we also performed a sensitivity analysis by excluding the two RCTs that included such patients; 6, 12 the pooled result was unaffected (WMD ¼ )1.1 days; 95% CI: )1.6 to )0.6). Of the seven RCTs included in the above analysis, three were conducted in Asia 7, 8, 13 and the remaining four in Analysis of these tertiary end-points, which are of potential clinical relevance, indicates that PPI treatment for ulcer bleeding reduces transfusion requirements and length of hospital stay. The magnitude of the benefit was greater in Asian than European trials. In the subgroup analyses, these outcomes only achieved statistical significance among the Asian RCTs although there was a clear trend towards significance among the European RCTs for improvement in hospital stay. We have previously reported 4 that PPI treatment for ulcer bleeding appears to be more efficacious in Asia than elsewhere regarding mortality, re-bleeding and surgical intervention rates, due possibly to an enhanced pharmacodynamic effect of PPIs among Asian patients. Possible reasons for such an effect might include a lower parietal cell mass, 14 higher prevalence of Helicobacter
5 SYSTEMATIC REVIEW: PPIS FOR ULCER BLEEDING 173 pylori infection 15 and higher prevalence of the slow metabolizer phenotype through genetic polymorphism for cytochrome P450 2C19, 16, 17 as previously discussed elsewhere. 4 On the contrary, the observed difference in efficacy regarding transfusion requirements and length of hospital stay could be related to the fact that all Asian trials used in these two analyses had been placebo-controlled, while all European trials (all but one in the analysis of length of hospitalization) had used an H 2 RA as the comparator treatment. However, this explanation is less likely because it contradicts the results of our main meta-analysis that found no difference in the corresponding subgroup analysis examining primary and secondary end-points. Finally, the observed differences between Asian and European patients for these tertiary end-points may be due to chance given the relatively small number of patients for whom data were obtainable. The true clinical significance of the observed effects of PPI treatment on transfusion requirements and length of hospital stay are undetermined. Although they are of small magnitude, they may be relevant financially given the frequency of hospitalization for ulcer bleeding. Consideration of these effects should be made during future cost-effectiveness analyses of PPI therapy for ulcer bleeding in health care systems of different countries. There was significant heterogeneity among the trials for transfusion requirements. It is important to try and identify any possible reasons for heterogeneity in a meta-analysis. The trial by Khuroo et al. 8 appeared to be an outlier (Figure 1), and its exclusion in a sensitivity analysis resolved the heterogeneity. This trial had found the largest difference in transfusion requirements in favour of PPI treatment. It differed from the others in that it was the only one to have included patients with spurting bleeding without using prerandomization endoscopic haemostatic treatment. Such patients would be expected to have high transfusion requirements because of ongoing bleeding and more severe episodes of re-bleeding. As a result, and assuming that PPI treatment was effective, this might have enhanced the difference in transfusion requirements between the two treatment arms. The precise criteria for administering blood transfusion were not given for that trial and two others. 5, 11 We acknowledge that differences among RCTs for the precise criteria for deciding to administer blood transfusion limit the strength of conclusions on the pooled effects. We considered whether mortality could have influenced the reporting of transfusion requirements, because those requirements would logically be lower among patients who died shortly after an episode of ulcer bleeding. Had this been the case, PPI treatment should have affected these two outcomes in opposite directions. For example, if there had been increased mortality among the PPI-treated patients, then there should have been a corresponding reduction in transfusion requirements. However, with the exception of one trial, 6 this was not the pattern of outcomes observed: PPI treatment otherwise affected mortality and transfusion requirements in the same direction. Mortality could also have influenced reporting of length of hospitalization; none of the trials distinguished length of hospital stay determined by death as opposed to hospital discharge. If mortality had influenced length of hospital stay, these should have been in opposite directions. For instance, if PPI treatment had decreased mortality, it should have increased the average length of hospital stay. None of the seven trials found a significant effect on mortality although two 5, 12 reported nonsignificant increases in mortality and shorter lengths of stay with PPI treatment. The remaining five trials reported non-significant reductions in mortality and shorter lengths of stay on PPI treatment. Thus, there is insufficient evidence to accept or refute the possibility that mortality may have significantly biased reporting of length of hospital stay. Nevertheless, the strength of the above conclusion is limited by the fact that hospital stay could have been affected by possible variability among RCTs regarding discharge criteria, which were reported only in two RCTs, 7, 13 and comorbidity, which could not be reliably quantified in the present meta-analysis. In conclusion, these planned analyses of predetermined tertiary end-points found small but potentially important reductions in transfusion requirements and length of hospital stay with PPI treatment for ulcer bleeding. Effects of PPI treatment on such clinically relevant outcomes should be part of any future costeffectiveness analyses in different health care delivery models. ACKNOWLEDGEMENTS Authors thank Ms Iris Gordon, Trial Search Coordinator, Cochrane Collaboration, Upper Gastrointestinal and Pancreatic Diseases Group, University of Leeds, UK for her help with the electronic literature search. Also
6 174 G. I. LEONTIADIS et al. grateful to Dr Linda McIntyre for assistance with designing the protocol for this review and subsequent data extraction. REFERENCES 1 Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004, issue 3. Article no: CD002094, pub2 (DOI: / CD pub2). 3 Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. Br Med J 2005; 330: Leontiadis GI, Sharma VK, Howden CW. Enhanced efficacy of proton pump inhibitor therapy for peptic ulcer bleeding in Asia: a post hoc analysis from the Cochrane Collaboration systematic review and meta-analysis. Aliment Pharmacol Ther 2005; 21: Coraggio F, Rotondano G, Marmo R, et al. Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Eur J Gastroenterol Hepatol 1998; 10: Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol 1997; 32: Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17: Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997; 336: Lanas A, Artal A, Blas JM, Arroyo MT, Lopez-Zaborras J, Sainz R. Effect of parenteral omeprazole and ranitidine on gastric ph and the outcome of bleeding peptic ulcer. J Clin Gastroenterol 1995; 21: Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: Pérez Flores R, García Molinero MJ, Herrero Quirós C, et al. Tratamiento de la hemorragia digestive alta de origen péptico: ranitidina intravenosa versus omeprazol intravenoso. Rev Esp Enferm Dig 1994; 86: Villanueva C, Balanzo J, Torras X, et al. Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study. Endoscopy 1995; 27: Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001; 111: Lam SK, Hasan M, Sircus W, Wong J, Ong GB, Prescott RJ. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 1980; 21: van Herwaarden MA, Samson M, van Nispen CHM, Mulder PGH, Smout AJPM. The effect of Helicobacter pylori eradication on intragastric ph during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13: Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60: Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996; 60:
Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication
Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 66 70. Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication G. HOLTMANN* & C. W. HOWDEN
More informationEffect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial
Aliment Pharmacol Ther 2003; 17: 211 216. doi: 10.1046/j.0269-2813.2003.01416.x Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical
More informationProton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review)
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P This
More informationProton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review)
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P This
More informationREVIEW ARTICLE. High-Dose vs Non High-Dose Proton Pump Inhibitors After Endoscopic Treatment in Patients With Bleeding Peptic Ulcer
REVIEW ARTICLE LESS IS MORE High-Dose vs Non High-Dose Proton Pump Inhibitors After Endoscopic Treatment in Patients With Bleeding Peptic Ulcer A Systematic Review and Meta-analysis of Randomized Controlled
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationCite this article as: BMJ, doi: /bmj f (published 31 January 2005)
Cite this article as: BMJ, doi:10.1136/bmj.38356.641134.8f (published 31 January 2005) Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding Grigoris I Leontiadis,
More informationScottish Medicines Consortium
Scottish Medicines Consortium esomeprazole, 40mg vial of powder for solution for intravenous injection or infusion (Nexium I.V. ) No. (578/09) AstraZeneca 09 October 2009 The Scottish Medicines Consortium
More informationIntermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis
Research Original Investigation Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis Hamita Sachar, MD; Keta Vaidya, MD; Loren Laine,
More informationA bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?
Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationOral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy
Yen et al. BMC Gastroenterology 2012, 12:66 RESEARCH ARTICLE Open Access Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful
More informationIntragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers
Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers LOREN LAINE, ABBID SHAH, and SHAHROOZ BEMANIAN Division of Gastrointestinal
More informationSetting The setting was primary and secondary care. The economic study was carried out in the UK.
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis Ford A C, Qume M, Moayyedi P, Arents N L, Lassen A T, Logan R F, McColl K E, Myres P,
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationOn-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding
On-Call Upper GI Bleeding John R Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Upper Gastrointestinal Bleeding 300,000000 hospitalizations/year
More informationSimon Everett. Consultant Gastroenterologist, SJUH, Leeds. if this is what greets you in the morning, you probably need to go see a doctor
Simon Everett Consultant Gastroenterologist, SJUH, Leeds if this is what greets you in the morning, you probably need to go see a doctor Presentation Audit data and mortality NICE guidance Risk assessment
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationACUTE UPPER GASTROINTESTINAL HEMORRHAGE: PHARMACOLOGIC MANAGEMENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationPantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: Prospective randomized controlled trial
Blackwell Publishing AsiaMelbourne, AustraliaJGHJournal of Gastroenterology and Hepatology0815 93192006 Blackwell Publishing Asia Pty Ltd200621716721Original Article Pantoprazole in bleeding peptic ulcerssa
More informationPeptic ulcers remain the most common cause of upper
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:33 47 STATE OF THE ART Endoscopic Therapy for Bleeding Ulcers: An Evidence-Based Approach Based on Meta-Analyses of Randomized Controlled Trials LOREN LAINE*
More informationClinical Study Effect of High-Dose Oral Rabeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcers
Gastroenterology Research and Practice Volume 2012, Article ID 317125, 8 pages doi:10.1155/2012/317125 Clinical Study Effect of High-Dose Oral Rabeprazole on Recurrent Bleeding after Endoscopic Treatment
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationJames Irwin Gastroenterology Department Palmerston North Hospital. Acute Medicine Meeting Hutt Hospital. June 21, 2015
The Management of Acute Upper Gastrointestinal Bleeding James Irwin Gastroenterology Department Palmerston North Hospital Acute Medicine Meeting Hutt Hospital June 21, 2015 Outline Common Definitions and
More informationFARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI
FARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI Edoardo V. Savarino, MD, PhD Professor of Gastroenterology Department of Surgery, Oncology and Gastroenterology University of Padua Italy COMMON
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2000, by the Massachusetts Medical Society VOLUME 343 A UGUST 3, 2000 NUMBER EFFECT OF INTRAVENOUS OMEPRAZOLE ON RECURRENT BLEEDING AFTER ENDOSCOPIC TREATMENT
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationACG Clinical Guideline: Management of Patients with Ulcer Bleeding
ACG Clinical Guideline: Management of Patients with Ulcer Bleeding Loren Laine, MD 1,2 and Dennis M. Jensen, MD 3 5 1 Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut,
More informationMeta Analysis. David R Urbach MD MSc Outcomes Research Course December 4, 2014
Meta Analysis David R Urbach MD MSc Outcomes Research Course December 4, 2014 Overview Definitions Identifying studies Appraising studies Quantitative synthesis Presentation of results Examining heterogeneity
More informationImproved risk assessment in upper GI bleeding
EDITORIAL Improved risk assessment in upper GI bleeding Acute upper GI bleeding is the most common GI emergency, with a reported incidence in various epidemiological studies ranging from 50 to over 100
More informationBritish Journal of Clinical Pharmacology. Zhixiang Jian 1,HuiLi 2, Nicholas S. Race 3,TingtingMa 4,HaoshengJin 1 and Zi Yin 1
British Journal of Clinical Pharmacology Br J Clin Pharmacol (2016) 82 880 889 880 META-ANALYSIS Is the era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers?
More informationPeptic ulcer bleeding is a common cause of hospitalization, Article
Annals of Internal Medicine Article Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding A Randomized Trial Joseph J.Y. Sung, MD; Alan Barkun, MD; Ernst J. Kuipers, MD; Joachim Mössner,
More informationAsia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding
Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding Joseph J Y Sung, 1 Francis K L Chan, 2 Minhu Chen, 3 Jessica Y L Ching, 3 K Y Ho, 4 Udom Kachintorn, 3 Nayoung Kim,
More informationGuideline for the Management of Upper Gastrointestinal Bleeding in Children
Guideline for the Management of Upper Gastrointestinal Bleeding in Children 1. Introduction Upper gastrointestinal (UGI) bleeding in children poses a challenge to paediatricians and paediatric surgeons.
More informationEfficacy and Safety of Proton Pump Inhibitors (PPIs) Plus Rebamipide for Endoscopic Submucosal Dissection-induced Ulcers: A Meta-analysis
ORIGINAL ARTICLE Efficacy and Safety of Proton Pump Inhibitors (PPIs) Plus Rebamipide for Endoscopic Submucosal Dissection-induced Ulcers: A Meta-analysis Jun Wang, Xufeng Guo, Chuncui Ye, Shijie Yu, Jixiang
More informationReview article: immediate-release proton-pump inhibitor therapy potential advantages
Aliment Pharmacol Ther 25; 22 (Suppl. 3): 25 3. Review article: immediate-release proton-pump inhibitor therapy potential advantages C. W. HOWDEN Division of Gastroenterology, Northwestern University Feinberg
More informationHigh Dose versus Low Dose Intravenous Pantoprazole in Bleeding Peptic Ulcer: A Randomized Clinical Trial
Original Article 137 High Dose versus Low Dose Intravenous Pantoprazole in Bleeding Peptic Ulcer: A Randomized Clinical Trial Abdol Rahim Masjedizadeh 1,2*, Eskandar Hajiani 1,2, Pezhman Alavinejad 1,2,
More informationEvidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co.
Evidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co. Meta-Analysis Defined A meta-analysis is: the statistical combination of two or more separate studies In other words: overview,
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION A Prospective Randomized Comparative Trial Showing That Prevents Rebleeding in Patients With Bleeding Peptic Ulcer After Successful Endoscopic Therapy Hwai-Jeng Lin, MD, FACG; Wen-Ching
More informationStudy population The study population comprised hypothetical patients with gastric and duodenal ulcer.
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationUGI BLEED. Dr. KPP Abhilash Associate Professor Department of Emergency Medicine Christian Medical College, Vellore
UGI BLEED Dr. KPP Abhilash Associate Professor Department of Emergency Medicine Christian Medical College, Vellore Outline UGI bleed: etiology and presentation Management: Non variceal / variceal bleed
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationToshihiro Nishizawa 1,2, Hidekazu Suzuki 2, Teppei Akimoto 1,3, Tadateru Maehata 1, Toshio Morizane 4, Takanori Kanai 2 and Naohisa Yahagi 1
Review Article Effects of preoperative proton pump inhibitor administration on bleeding after gastric endoscopic submucosal dissection: A systematic review and meta-analysis United European Gastroenterology
More informationResearch Article Management of Peptic Ulcer Bleeding in Different Case Volume Workplaces: Results of a Nationwide Inquiry in Hungary
Gastroenterology Research and Practice Volume 2012, Article ID 956434, 6 pages doi:10.1155/2012/956434 Research Article Management of Peptic Ulcer Bleeding in Different Case Volume Workplaces: Results
More informationBritish Society of Gastroenterology. St. Elsewhere's Hospital. National Comparative Audit of Blood Transfusion
British Society of Gastroenterology UK Com parat ive Audit of Upper Gast roint est inal Bleeding and t he Use of Blood Transfusion Extract December 2007 St. Elsewhere's Hospital National Comparative Audit
More informationHow to Conduct a Meta-Analysis
How to Conduct a Meta-Analysis Faculty Development and Diversity Seminar ludovic@bu.edu Dec 11th, 2017 Periodontal disease treatment and preterm birth We conducted a metaanalysis of randomized controlled
More informationNumber of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI
Clinical Approach to the Patient t with Dyspepsia William D. Chey, MD, FACG Professor of Medicine University of Michigan Prevalence of Endoscopic Findings in Individuals with Dyspepsia Systematic Review
More informationAnticoagulants are a contributing factor. Other causes are Mallory-Weiss tears, AV malformations, and malignancy and aorto-enteric fistula.
Upper GI Bleeding EMU2018 Dr. Walter Himmel MD Incidence: In non-cirrhotics, the commonest causes are peptic ulcer disease (50%) followed by erosive gastritis. In cirrhotic patients, variceal bleeding
More information5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA
5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for
More informationOutcome of endoscopic treatment for peptic ulcer bleeding: Is a second look necessary? A meta-analysis
Outcome of endoscopic treatment for peptic ulcer bleeding: Is a second look necessary? A meta-analysis Riccardo Marmo, MD, Gianluca Rotondano, MD, Maria Antonia Bianco, MD, Roberto Piscopo, MD, Antonio
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationDeveloping Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada
Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationSystematic review of proton pump inhibitors for the acute treatment of re ux oesophagitis
Aliment Pharmacol Ther 2001; 15: 1729±1736. Systematic review of proton pump inhibitors for the acute treatment of re ux oesophagitis S. J. EDWARDS*, T. LIND & L. LUNDELLà *Outcomes Research, AstraZeneca,
More informationPeptic ulcer bleeding remains the most common cause of hospitalization
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:311 316 Predicting Mortality in Patients With Bleeding Peptic Ulcers After Therapeutic Endoscopy PHILIP W. Y. CHIU,* ENDERS K. W. NG,* FRANCES K. Y. CHEUNG,*
More informationData extraction. Specific interventions included in the review Dressings and topical agents in relation to wound healing.
Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds Bradley M, Cullum N, Nelson E A, Petticrew M, Sheldon T, Torgerson D Authors' objectives
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationSYSTEMATIC REVIEW: AN APPROACH FOR TRANSPARENT RESEARCH SYNTHESIS
SYSTEMATIC REVIEW: AN APPROACH FOR TRANSPARENT RESEARCH SYNTHESIS A Case Study By Anil Khedkar, India (Masters in Pharmaceutical Science, PhD in Clinical Research Student of Texila American University)
More informationNew Techniques. Incidence of Peptic Ulcer. Changing. Contents - with an emphasis on peptic ulcer bleeding. Cause of death in peptic ulcer bleeding
Contents - with an emphasis on peptic ulcer bleeding New Techniques in Treating GI Bleeding Incidence and cause of death Acid suppression Endoscopic hemostasis Prediction of rebleeding and death Second
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationTurning off the tap: Endoscopy Blood & Guts: Transfusion and bleeding in the medical patient
Turning off the tap: Endoscopy Blood & Guts: Transfusion and bleeding in the medical patient John Greenaway 1 Turning off the tap: Endoscopy Answer the questions Benefits and risks of endoscopy Urgency
More informationEugenia Lauret, Jesús Herrero, Lorena Blanco, Olegario Castaño, Maria Rodriguez, Isabel Pérez, Verónica Alvarez, Adolfo Suárez, and Luis Rodrigo
Gastroenterology Research and ractice Volume 2013, Article ID 584540, 5 pages http://dx.doi.org/10.1155/2013/584540 Clinical Study Epidemiological Clinical Features and Evolution of Gastroduodenal Ulcer
More informationPre-endoscopic erythromycin administration in upper gastrointestinal bleeding: an updated meta-analysis and systematic review
ORIGINAL ARTICLE Annals of Gastroenterology (2016) 29, 1-6 Pre-endoscopic erythromycin administration in upper gastrointestinal bleeding: an updated meta-analysis and systematic review Rubayat Rahman a,
More informationSupplementary Online Content
Supplementary Online Content Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for highrisk bleeding ulcers: systematic review and meta-analysis. JAMA Intern Med. Published
More informationEmergency Surgery Board Department of General Surgery Rambam Health Care Campus
Emergency Surgery Board Department of General Surgery Rambam Health Care Campus Surgical Complications of Peptic Ulcer Disease Bleeding Case Presentation and Review of the Literature Case Presentation
More informationUpper GI Bleeding. HH Tsai MD FRCP FECG Consultant Gastroenterologist
Upper GI Bleeding HH Tsai MD FRCP FECG Consultant Gastroenterologist Financial Disclosures I have no financial relationship with any manufacturer or supplier of any product mentioned in this talk. GI Audits:
More informationEarly Management of the Patient with Acute GI Bleeding
Early Management of the Patient with Acute GI Bleeding Dr Sarah Hearnshaw Consultant Gastroenterologist Newcastle upon Tyne NHS Trust Go through.. Stats Transfusion / resuscitation PPIs When to call us
More informationUpper gastrointestinal bleeding in children. Nguyễn Diệu Vinh, MD Department of Gastroenterology
Upper gastrointestinal bleeding in children Nguyễn Diệu Vinh, MD Department of Gastroenterology INTRODUCTION Upper gastrointestinal (UGI) bleeding : arising proximal to the ligament of Treitz in the distal
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationChapter 34. Prevention of Clinically Significant Gastrointestinal Bleeding in Intensive Care Unit Patients
Chapter 34. Prevention of Clinically Significant Gastrointestinal Bleeding in Intensive Care Unit Patients Daniel D. Dressler, MD Mark V. Williams, MD Kimberly Rask, MD, PhD Emory University Schools of
More informationProton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs
ORIGINAL ARTICLE Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs Yuki Sakamoto, Tadashi Shimoyama, Satoru Nakagawa,
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationPROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: Am J Gastroenterol Jan;105(1): Epub 2009 Nov 10.
PROTON PUMP INHIBITOR AND CLOPIDOGREL INTERACTION: FACT OR FICTION? 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時, 須獲得原期刊之同意授權 Am J Gastroenterol. 2010 Jan;105(1):34-41. Epub 2009 Nov 10. Introduction Current consensus
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first
More informationSangrado Gastrointestinal Alto Upper GI Bleeding
Sangrado Gastrointestinal Alto Upper GI Bleeding Curso Internacional Retos Clinicos en la Gastroenterologia de Urgencias Asociacion Colombiana de Gastroenterologia 31 de Agosto, 2012 Pereira, Risaralda
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Closed reduction methods for acute anterior shoulder dislocation [Cochrane Protocol] Kanthan Theivendran, Raj Thakrar, Subodh Deshmukh,
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationHeartburn is a common symptom among adults in
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:553 563 Early Heartburn Relief With Proton Pump Inhibitors: A Systematic Review and Meta-analysis of Clinical Trials KENNETH R. MCQUAID*, and LOREN LAINE
More informationSystematic Review of the Predictors of Recurrent Hemorrhage After Endoscopic Hemostatic Therapy for Bleeding Peptic Ulcers
American Journal of Gastroenterology ISSN 0002-9270 C 2008 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2008.02070.x Published by Blackwell Publishing CLINICAL REVIEWS Systematic Review of
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationSurvey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly
Aliment Pharmacol Ther 1999; 13: 813±817. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly R. BOUTET, M. WILCOCK & I. MACKENZIE 1 Department of
More informationUpper gastrointestinal (GI) bleeding represents a substantial
Clinical Guidelines Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding Alan Barkun, MD, MSc; Marc Bardou, MD, PhD; and John K. Marshall, MD, MSc, for the Nonvariceal
More informationHigh Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up
Gut and Liver, Vol. 7, No. 2, March 2013, pp. 175-181 ORiginal Article High Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up Hyuk Yoon, Sang Gyun Kim, Hyun Chae Jung, and In Sung Song
More informationEsomeprazole versus omeprazole for the eradication of Helicobacter pylori infection
International Journal of Community Medicine and Public Health Ageeli R et al. Int J Community Med Public Health. 2018 Jul;5(7):2686-2691 http://www.ijcmph.com pissn 2394-6032 eissn 2394-6040 Original Research
More informationTHE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 98, No. 12, by Am. Coll. of Gastroenterology ISSN /03/$30.00
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 98, No. 12, 2003 2003 by Am. Coll. of Gastroenterology ISSN 0002-9270/03/$30.00 Published by Elsevier Inc. doi:10.1016/j.amjgastroenterol.2003.07.003 An Update
More informationDrain versus no-drain after gastrectomy for patients with advanced gastric cancer Student EBM presentations
Drain versus no-drain after gastrectomy for patients with advanced gastric cancer Student EBM presentations Selali Fiamanya & Jawaad Farrukh University of Oxford October 2014 The question Mr X is a 56
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationComparison of adrenaline injection and bipolar electrocoagulation for the arrest of peptic ulcer bleeding
Gut 1999;44:715 719 715 Division of Gastroenterology, Department of Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China H-J Lin G-Y Tseng C-L Perng F-Y Lee F-Y Chang S-D Lee Correspondence
More informationReview article: similarities and differences among delayed-release proton-pump inhibitor formulations
Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 20 24. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations J. R. HORN* & C. W. HOWDEN *Department of Pharmacy,
More informationInappropriate Use of Intravenous Pantoprazole: Extent of the Problem and Successful Solutions
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1207 1214 Inappropriate Use of Intravenous Pantoprazole: Extent of the Problem and Successful Solutions GILAAD G. KAPLAN,* DUANE BATES, DAWN MCDONALD, REMO
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationDigestive and Liver Disease
Digestive and Liver Disease 46 (2014) 313 317 Contents lists available at ScienceDirect Digestive and Liver Disease jou rnal h om epage: www.elsevier.com/locate/dld Alimentary Tract Time trends and outcome
More information